However, TERTp mutation may be a second genetic event following oncogenic activation, such as IDH mutation in diffuse gliomas, BRAF V600E mutation in thyroid cancer, and FGFR3 mutation in urothelial carcinoma29,31,32. Here, IDH1 is linked to thyroid gland carcinoma.